In a report released today, Asthika Goonewardene from Truist Financial maintained a Hold rating on Gilead Sciences (GILD – Research Report).

Gilead Sciences Inc. closed 8.11% short of its 52-week high of $119.96, which the company achieved on March 10th.

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

We recently published a list of 13 Most Undervalued NASDAQ Stocks To Buy According To Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for virology, oncology and other therapeutic areas in the United States, Europe, and ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other most undervalued NASDAQ stocks to buy according to hedge funds. The NASDAQ Index closed ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta. Hear how Devi's background has shaped her approach to developing new medicines and to bringing ...